Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 6/20 | 0.36 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL914555 | 0.99 | SLC2A1 (0.37) | SLC2A1HTR7HTR1ADRD2HTR6 | |
| SCHEMBL12433987 | 0.93 | SLC2A1 (0.34) | SLC2A1HTR7HTR1ADRD2HTR6 | |
| SCHEMBL14135073 | 0.93 | SLC2A1 (0.34) | SLC2A1HTR7HTR1ADRD2HTR6 | |
| SCHEMBL2315726 | 0.93 | SLC2A1 (0.34) | SLC2A1HTR7HTR1ADRD2HTR6 | |
| SCHEMBL6964134 | 0.91 | HTR7 (0.39) | HTR7HTR1ADRD2HTR6KCNH2 | |
| SCHEMBL6965055 | 0.91 | HTR7 (0.39) | SLC2A1HTR7HTR1ADRD2HTR6 | |
| Hydrochloric Acid SCHEMBL914237 | 0.91 | HTR7 (0.39) | HTR7HTR1ADRD2HTR6KCNH2 | |
| Hydrochloric Acid SCHEMBL913258 | 0.91 | HTR7 (0.38) | SLC2A1HTR7HTR1ADRD2HTR6 | |
| SCHEMBL12971780 | 0.90 | SLC2A1 (0.39) | SLC2A1HTR1AKMT2AKCNH2MCHR1 | |
| SCHEMBL6963842 | 0.90 | SLC2A1 (0.39) | SLC2A1HTR1AKMT2AKCNH2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183366-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| US-8183366-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| US-20110015180-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-20110015180-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-7858781-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2010-12-28 | — | — | US | disclosed |
| US-7858781-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2010-12-28 | — | — | US | disclosed |
| EP-1720859-B1 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20070155721-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2007-07-05 | — | — | US | disclosed |
| US-20070155721-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015180-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | SLC2A1 820/4885HTR7 1237/4885HTR1A 1607/4885 |
| US-20070155721-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | SLC2A1 822/4885HTR7 1241/4885HTR1A 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.